Clinical Trials Directory

Trials / Completed

CompletedNCT02274870

Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery

Liposomal Bupivacaine for Total Knee Arthroplasty Postoperative Analgesia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
65 (actual)
Sponsor
Northwell Health · Academic / Other
Sex
All
Age
18 Years – 74 Years
Healthy volunteers
Not accepted

Summary

Continuous femoral nerve blocks (CFNB) provide effective pain control to patients undergoing total knee replacement (TKR). However the resulting motor blockade can lead to decreased quadriceps muscle strength and delayed functional recovery.The purpose of this study is to compare the effect of Liposome Bupivacaine infiltration into the knee to CFNB on pain control and functional recovery

Detailed description

This is a prospective, randomized, active controlled study in patients undergoing total knee replacement. The objective of this study is to compare the efficacy of Liposome Bupivacaine, in managing postoperative pain, to standard of care CFNB. Following informed consent, patients will be randomized to one of two groups, Liposome Bupivacaine or active control, CFNB group. 266 mg Liposome Bupivacaine plus Bupivicaine HCL (150mg) will be administered via local joint infiltration around the knee joint prior to wound closure. In the control group a CFNB will be placed for 48hrs prior to surgery. Outcomes measured included pain at rest, movement and quadriceps muscle strength on the first and second postoperative day. It is hypothesized that Liposome Bupivacaine will provide effective pain control and improved preservation of quadriceps muscle strength, in comparison to CFNB.

Conditions

Interventions

TypeNameDescription
DRUGLiposome BupivacaineAdministered via local tissue infiltration around the knee joint
DRUGBupivacaine HClAdministered via CFNB

Timeline

Start date
2014-11-01
Primary completion
2016-12-01
Completion
2017-01-01
First posted
2014-10-24
Last updated
2018-06-14
Results posted
2018-06-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02274870. Inclusion in this directory is not an endorsement.